Management Infertility by Hormones Replacement Therapy in Women with Polycystic Ovarian Syndrome

What is it about?

Polycystic ovary syndrome (PCOS) is an endocrine-metabolic disorder characterized by multiple hormonal imbalances; the clinical presentation is dominated by manifestations of hyperandrogenism, which generates short- and long-term consequences on female health sterility, infertility is one of the most alarming associated morbidities. Forty women (28.9 ± 0.8 years old) with the polycystic ovarian syndrome had infertility and there were enrolled in these clinical trials and randomly allocated into two groups. Group one and Group two were given treated infertility drugs (Clomid 5 mg for 5 days) and recombinant follicle-stimulating hormone (FSH) 75 IU for a long and short duration to get pregnant. Serum testosterone, progesterone, follicle-stimulating hormone (FSH), and luteinizing hormone (LH) of both groups were measured when women were diagnosed with PCOS. The results showed that women which treated with low-dose recombinant FSH 75 IU for 3 days consequently (Group one) have significant decreased LH, while progesterone and FSH significantly increased after being treated by hormone therapy P ≥ 0.05 while after treatment with recombinant FSH IU for 5 days (Group two), the result showed non-significant effect as compared with the first group. Concluded: Increase pregnant rate and decrease over-stimulation syndrome among infertile women associated with the polycystic ovarian syndrome, when treated with an applicated low dose and short term by rFSH hormone.

Featured Image

Photo by Reproductive Health Supplies Coalition on Unsplash

Photo by Reproductive Health Supplies Coalition on Unsplash